Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 143.03 |
| Open | 144.00 |
| Bid | 139.51 x 100 |
| Ask | 139.86 x 300 |
| Day's range | 139.64 - 144.09 |
| 52-week range | 89.04 - 148.37 |
| Volume | |
| Avg. volume | 908,477 |
| Market cap | 14.064B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 56.61 |
| EPS (TTM) | 2.47 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 155.75 |
Simply Wall St.Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations
Neurocrine Biosciences ( NASDAQ:NBIX ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from...
- GuruFocus.com
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
INGREZZA drives strong sales while new drug approvals and a solid cash position underscore a promising future.
GuruFocus.comDecoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
Financial Performance and Market Dynamics: A SWOT Analysis of Neurocrine Biosciences Inc
© 2024 Yahoo. All rights reserved.